Hydrocortisone is the Preferred Corticosteroid for Severe Pneumonia
For patients with severe community-acquired pneumonia requiring ICU admission, hydrocortisone should be used as the first-line corticosteroid at a dose of 200 mg/day intravenously, not dexamethasone. The recommended regimen is 200 mg daily (typically divided as 50 mg every 6 hours) for 4-7 days based on clinical improvement, followed by tapering over a total treatment duration of 8-14 days 1.
Evidence Hierarchy and Rationale
The 2019 ATS/IDSA guidelines recommend against routine corticosteroid use in severe CAP, providing only conditional recommendations 2. However, this guidance predates the landmark CAPE COD trial (2023), which fundamentally changed the evidence landscape.
Why Hydrocortisone Over Dexamethasone
The CAPE COD trial provides the highest quality evidence: This phase 3 RCT of 795 ICU patients with severe CAP demonstrated that hydrocortisone reduced 28-day mortality from 11.9% to 6.2% (absolute risk reduction of 5.6%, P=0.006) 1. This represents a 48% relative risk reduction in mortality—a clinically dramatic benefit.
Multiple recent meta-analyses (2024-2025) consistently show:
- Hydrocortisone specifically reduces mortality by approximately 50% in severe CAP (RR 0.35-0.48) 3, 4, 5
- Dexamethasone, methylprednisolone, and prednisolone show no significant mortality benefit in severe bacterial CAP 3, 4, 5
- Network meta-analyses rank hydrocortisone as having the highest probability of being the most effective corticosteroid for reducing 30-day mortality 5
Additional Benefits of Hydrocortisone
Beyond mortality reduction, hydrocortisone in the CAPE COD trial:
- Reduced need for mechanical ventilation (18.0% vs 29.5%, HR 0.59) 1
- Decreased vasopressor initiation (15.3% vs 25.0%, HR 0.59) 1
- Lowered rates of acute respiratory distress syndrome and shock 4
Specific Dosing Protocol
Hydrocortisone regimen:
- Initial dose: 200 mg/day IV (typically 50 mg every 6 hours)
- Duration: 4-7 days at full dose, adjusted by clinical response
- Tapering: Gradual taper over total 8-14 days 1, 6
The FDA labeling for dexamethasone suggests 0.5-9 mg/day for various conditions, with higher doses for shock 7, but this generic guidance lacks the specific evidence base that hydrocortisone has for severe CAP.
Critical Patient Selection Criteria
Appropriate candidates (based on CAPE COD):
- ICU admission for severe CAP
- Respiratory failure of <24 hours duration
- CRP >200 mg/L may identify optimal responders 8
Exclusions:
- Influenza pneumonia (corticosteroids may increase mortality) 2, 9
- Aspiration pneumonia 6
- Myelosuppression 6
- Non-severe CAP (no benefit demonstrated) 2, 6
Important Caveats and Safety
Common pitfall: The evidence for hydrocortisone in severe CAP should not be extrapolated to dexamethasone. While dexamethasone is effective for severe COVID-19 (6 mg daily for 10 days reduces mortality) 9, this benefit does not translate to bacterial CAP 3, 4, 5.
Monitoring requirements:
- Hyperglycemia is the primary adverse effect—patients require higher insulin doses during the first week 1
- No increased rates of hospital-acquired infections or gastrointestinal bleeding were observed in CAPE COD 1
- The dose range (200 mg hydrocortisone equivalent) falls within the safety profile established in prior studies 2
For septic shock complicating CAP: The Surviving Sepsis Campaign recommendations for refractory septic shock remain applicable, which may involve hydrocortisone 50 mg IV every 6 hours plus fludrocortisone 50 μg daily 2, 9.
Algorithm for Clinical Decision-Making
- Confirm severe CAP requiring ICU admission
- Exclude influenza, aspiration pneumonia, immunosuppression
- Verify respiratory failure duration <24 hours
- Check CRP (>200 mg/L suggests higher benefit potential)
- Initiate hydrocortisone 200 mg/day IV within 24 hours of ICU admission
- Monitor glucose closely and adjust insulin accordingly
- Continue 4-7 days based on clinical improvement
- Taper gradually over remaining days to complete 8-14 day course
The 2025 French guidelines now explicitly recommend hydrocortisone for severe CAP requiring critical care based on the CAPE COD results 6, representing the most current expert consensus that supersedes older guidance against corticosteroid use.